Wholesale Crikzo 200mg for US Clinics | Ernest Oncology India Supply

Crikzo 200mg Capsule: Targeted Tyrosine Kinase Inhibition for Advanced ALK/ROS1 Cancers

Are you seeking a reliable Crikzo 200mg capsule exporter from India? Ernest Oncology, a premier division of Ernest Pharmaceutical Pvt. Ltd., is a globally recognized supplier and bulk distributor of advanced oral targeted therapies. We operate a high-integrity, regulatory-compliant supply chain serving the USA, UK, Australia, and South Africa, ensuring that critical oncology medications reach healthcare facilities with pharmaceutical-grade security and efficient global logistics.

Detailed Product Overview: What is Crikzo 200mg?

Crikzo 200mg is a high-potency oral capsule containing the active pharmaceutical ingredient Crizotinib. It belongs to the class of medications known as Tyrosine Kinase Inhibitors (TKIs).

Manufactured by Hetero Healthcare Ltd., Crikzo 200mg is precision-engineered to treat specific genetically-driven malignancies. While 250mg is the standard starting dose for many adults, the 200mg strength is vital for pediatric patients (based on Body Surface Area) and adult patients requiring dose adjustments due to hepatic impairment or to manage treatment-related side effects.

Primary Therapeutic Indications

Crikzo 200 mg Capsule is clinically indicated for:

1. ALK-Positive Metastatic NSCLC: Treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive.

2. ROS1-Positive Metastatic NSCLC: Treatment of metastatic NSCLC in adults with ROS1-positive gene rearrangements.

3. Relapsed/Refractory Systemic ALCL: For pediatric patients (1 year+) and young adults with ALK-positive Anaplastic Large Cell Lymphoma (ALCL).

4. Inflammatory Myofibroblastic Tumor (IMT): For adult and pediatric patients with unresectable or recurrent ALK-positive IMT.

Mechanism of Action: How Crikzo 200 mg Works

Crizotinib targets the molecular drivers of cancer by inhibiting specific signaling proteins:

• Inhibition of ALK/ROS1: It selectively blocks the activity of ALK, ROS1, and c-MET tyrosine kinases. In many cancers, these genes fuse with other genes, creating abnormal "on" switches for uncontrolled cell division.

• Cell Cycle Arrest: By binding to these kinases, Crikzo stops the growth signaling pathway. This prevents the cancer from spreading and can lead to tumor shrinkage.

• Precision Targeting: Unlike traditional chemotherapy, Crizotinib is designed to target cells with specific genetic mutations, significantly reducing damage to healthy, non-cancerous tissues.

Administration and Safety Guidelines

• Dosage: Typically taken twice daily, with or without food. The 200mg dose is frequently used for pediatric patients or as a first-level dose reduction for adults.

• Instructions: Swallow the capsule whole; do not chew, crush, or open it. Consistency in timing is essential for therapeutic efficacy.

• Key Precautions:

• Hepatotoxicity: Liver function must be monitored every two weeks during the first two months.

• Vision Changes: Patients may experience "trailing lights" or blurred vision, especially in low-light conditions.

• QT Prolongation: Regular ECG monitoring is advised to ensure heart rhythm safety.

• Avoid Grapefruit: Grapefruit products can increase the drug’s concentration to toxic levels and should be avoided.

Why Source Crikzo 200 mg from Ernest Oncology?

• Direct Indian Exporter: Authentic supply from Hetero Healthcare with GMP-certified storage and competitive bulk pricing.

• Logistics Authority: Expertise in the specialized import regulations of the USA, UK, Australia, and South Africa.

• Cold-Chain Management: Strict temperature-controlled shipping to maintain the stability of oral targeted therapies.

• Bulk Supply Stability: We specialize in fulfilling large-scale orders for oncology centers and regional distributors, ensuring no interruption in patient care.